Inotrem gains rights to TREM1 biomarker for cardiovascular diseases

Inotrem S.A. (Paris, France) gained exclusive, worldwide rights to the soluble triggering receptor expressed on myeloid cells 1 (TREM1) biomarker for use in cardiovascular diseases, specifically acute myocardial infarction (MI), from the Universities of Paris Sorbonne and of Lorraine, Inserm and Assistance Publique - Hôpitaux de Paris. Financial terms were not disclosed...